This trial will study whether Ruxolitinib cream, with or without phototherapy, can help treat vitiligo in people for whom the affected area does not exceed 10% of their body.
1 Primary · 8 Secondary · Reporting Duration: Approximately 14 months
Experimental Treatment
50 Total Participants · 2 Treatment Groups
Primary Treatment: NB-UVB phototherapy · No Placebo Group · Phase 2
Age 12 - 99 · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Washington | 33.3% |
Georgia | 22.2% |
Massachusetts | 22.2% |
Other | 22.2% |
18 - 65 | 87.5% |
65+ | 12.5% |
UC Davis Health | 33.3% |
Delricht Clinical Research - Clinedge - Ppds Baton Rouge | 16.7% |
Principle Research Solutions | 33.3% |
Other | 16.7% |
Met criteria | 55.6% |
Did not meet criteria | 44.4% |
0 | 100.0% |
Phone Call | 100.0% |